Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Wilms Tumor × Etoposide × Clear all

Phase

Phase 2 4 Phase 1 3 Phase 3 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 16 Small Cell Lung Carcinoma 15 Lymphoma, Large B-Cell, Diffuse 14 Lymphoma 14 Leukemia, Myeloid, Acute 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Lymphoma, Non-Hodgkin 11 Leukemia 10 Lymphoma, Mantle-Cell 9 Lymphoma, Follicular 9 Lung Neoplasms 9 Carcinoma, Non-Small-Cell Lung 7 Burkitt Lymphoma 6 Lymphoma, Large-Cell, Immunoblastic 5 Lymphoma, B-Cell 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Recurrence 4 Lymphoma, Large-Cell, Anaplastic 4 Lymphoma, B-Cell, Marginal Zone 4 Waldenstrom Macroglobulinemia 3 Plasmablastic Lymphoma 3 Lymphoma, T-Cell 3 Lymphoma, Primary Effusion 3 Leukemia, Myelomonocytic, Acute 3 Leukemia, Monocytic, Acute 3 Leukemia, Megakaryoblastic, Acute 3 Leukemia, Erythroblastic, Acute 3 Immunoblastic Lymphadenopathy 3 Dendritic Cell Sarcoma, Interdigitating 3 Congenital Abnormalities 3

Interventions

Temozolomide 3 Filgrastim 2 Drug Therapy 2 talazoparib 1 sargramostim 1 pembrolizumab 1 oblimersen 1 irinotecan sucrosofate 1 etoposide phosphate 1 entrectinib 1 X-Rays 1 Vincristine 1 Specimen Handling 1 Radiotherapy 1 Radiosurgery 1 Proteasome Inhibitors 1 Phantoms, Imaging 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Monatide (IMS 3015) 1 Microarray Analysis 1 Lenalidomide 1 Isotretinoin 1 Irinotecan 1 Immunomodulating Agents 1 Immunohistochemistry 1 Ifosfamide 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Etoposide 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05384821 2026-03-18

MetroWilms

Centre Oscar Lambret

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡